BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dash RP, Jayachandra Babu R, Srinivas NR. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. Eur J Drug Metab Pharmacokinet 2017;42:915-33. [PMID: 28374336 DOI: 10.1007/s13318-017-0411-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Sun D, Liu J, Wang Y, Dong J. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Front Oncol 2022;12:944537. [DOI: 10.3389/fonc.2022.944537] [Reference Citation Analysis]
2 Salata GC, Lopes LB. Phosphatidylcholine-Based Nanoemulsions for Paclitaxel and a P-Glycoprotein Inhibitor Delivery and Breast Cancer Intraductal Treatment. Pharmaceuticals 2022;15:1110. [DOI: 10.3390/ph15091110] [Reference Citation Analysis]
3 Alves R, Gonçalves AC, Jorge J, Almeida AM, Sarmento-ribeiro AB. Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines 2022;10:1158. [DOI: 10.3390/biomedicines10051158] [Reference Citation Analysis]
4 Flipo M, Frita R, Bourotte M, Martínez-Martínez MS, Boesche M, Boyle GW, Derimanov G, Drewes G, Gamallo P, Ghidelli-Disse S, Gresham S, Jiménez E, de Mercado J, Pérez-Herrán E, Porras-De Francisco E, Rullas J, Casado P, Leroux F, Piveteau C, Kiass M, Mathys V, Soetaert K, Megalizzi V, Tanina A, Wintjens R, Antoine R, Brodin P, Delorme V, Moune M, Djaout K, Slupek S, Kemmer C, Gitzinger M, Ballell L, Mendoza-Losana A, Lociuro S, Deprez B, Barros-Aguirre D, Remuiñán MJ, Willand N, Baulard AR. The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis. Sci Transl Med 2022;14:eaaz6280. [PMID: 35507672 DOI: 10.1126/scitranslmed.aaz6280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Teleanu RI, Preda MD, Niculescu A, Vladâcenco O, Radu CI, Grumezescu AM, Teleanu DM. Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier. Pharmaceutics 2022;14:987. [DOI: 10.3390/pharmaceutics14050987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pitsillou E, Liang JJ, Beh RC, Prestedge J, Catak S, Hung A, Karagiannis TC. Identification of novel bioactive compounds from Olea europaea by evaluation of chemical compounds in the OliveNet™ library: in silico bioactivity and molecular modelling, and in vitro validation of hERG activity. Computers in Biology and Medicine 2022;142:105247. [DOI: 10.1016/j.compbiomed.2022.105247] [Reference Citation Analysis]
7 Loos NH, Retmana IA, Li W, Martins ML, Lebre MC, Sparidans RW, Beijnen JH, Schinkel AH. ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106137] [Reference Citation Analysis]
8 Rathi S, Griffith JI, Zhang W, Zhang W, Oh JH, Talele S, Sarkaria JN, Elmquist WF. The influence of the blood-brain barrier in the treatment of brain tumours. J Intern Med 2022. [PMID: 35040235 DOI: 10.1111/joim.13440] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 F Martins ML, Loos NHC, Mucuk S, de Jong D, Lebre MC, Rosing H, Tibben M, Beijnen JH, Schinkel AH. P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Mol Pharm 2021;18:4371-84. [PMID: 34730366 DOI: 10.1021/acs.molpharmaceut.1c00553] [Reference Citation Analysis]
10 Sharma P, Singh N, Sharma S. ATP binding cassette transporters and cancer: revisiting their controversial role. Pharmacogenomics 2021;22:1211-35. [PMID: 34783261 DOI: 10.2217/pgs-2021-0116] [Reference Citation Analysis]
11 Kaczor A, Szemerédi N, Kucwaj-Brysz K, Dąbrowska M, Starek M, Latacz G, Spengler G, Handzlik J. Computer-Aided Search for 5-Arylideneimidazolone Anticancer Agents Able To Overcome ABCB1-Based Multidrug Resistance. ChemMedChem 2021;16:2386-401. [PMID: 33929088 DOI: 10.1002/cmdc.202100252] [Reference Citation Analysis]
12 Iacone Y, Morais TP, David F, Delicata F, Sandle J, Raffai T, Parri HR, Weisser JJ, Bundgaard C, Klewe IV, Tamás G, Thomsen MS, Crunelli V, Lőrincz ML. Systemic administration of ivabradine, a hyperpolarization-activated cyclic nucleotide-gated channel inhibitor, blocks spontaneous absence seizures. Epilepsia 2021;62:1729-43. [PMID: 34018186 DOI: 10.1111/epi.16926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Jackson CGCA, Hung T, Segelov E, Barlow P, Prenen H, McLaren B, Hung NA, Clarke K, Chao TY, Dai MS, Yeh HT, Cutler DL, Kramer D, He J, Zhi J, Chan WK, Kwan R, Deva S. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. Br J Clin Pharmacol 2021. [PMID: 33960504 DOI: 10.1111/bcp.14886] [Reference Citation Analysis]
14 Ramos H, Soares MIL, Silva J, Raimundo L, Calheiros J, Gomes C, Reis F, Monteiro FA, Nunes C, Reis S, Bosco B, Piazza S, Domingues L, Chlapek P, Vlcek P, Fabian P, Rajado AT, Carvalho ATP, Veselska R, Inga A, Pinho E Melo TMVD, Saraiva L. A selective p53 activator and anticancer agent to improve colorectal cancer therapy. Cell Rep 2021;35:108982. [PMID: 33852837 DOI: 10.1016/j.celrep.2021.108982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rowbottom C, Pietrasiewicz A, Tuczewycz T, Grater R, Qiu D, Kapadnis S, Trapa P. Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats. Pharmacol Res Perspect 2021;9:e00740. [PMID: 33660938 DOI: 10.1002/prp2.740] [Reference Citation Analysis]
16 Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, Robertson PL, Garton HJ, Wahl DR, Parmar H, Sarkaria JN, Kline C, Mueller S, Nicolaides T, Glasser C, Leary SE, Venneti S, Kumar-Sinha C, Chinnaiyan AM, Mody R, Pai MP, Phoenix TN, Marini BL, Koschmann C. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. J Clin Invest 2020;130:5313-25. [PMID: 32603316 DOI: 10.1172/JCI133310] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
17 Abdallah IM, Al-Shami KM, Yang E, Kaddoumi A. Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice. Int J Mol Sci 2021;22:1231. [PMID: 33513818 DOI: 10.3390/ijms22031231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Abd-elazeem OM, Osman NA, El-shenawy NS. Bioactive Compounds of Seaweeds and Their Effects on Certain Types of Cancer. Avicenna J Med Biochem 2020;8:112-9. [DOI: 10.34172/ajmb.2020.16] [Reference Citation Analysis]
19 Guieu B, Jourdan JP, Dreneau A, Willand N, Rochais C, Dallemagne P. Desirable drug-drug interactions or when a matter of concern becomes a renewed therapeutic strategy. Drug Discov Today 2021;26:315-28. [PMID: 33253919 DOI: 10.1016/j.drudis.2020.11.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Lai JI, Tseng YJ, Chen MH, Huang CF, Chang PM. Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. Front Oncol 2020;10:561936. [PMID: 33312947 DOI: 10.3389/fonc.2020.561936] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
21 Zhang H, Xu H, Ashby CR Jr, Assaraf YG, Chen ZS, Liu HM. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev 2021;41:525-55. [PMID: 33047304 DOI: 10.1002/med.21739] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
22 Geisslinger F, Müller M, Vollmar AM, Bartel K. Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance-A Mini Review. Front Oncol 2020;10:1156. [PMID: 32733810 DOI: 10.3389/fonc.2020.01156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
23 Farman S, Javed A, Arshia, Khan KM, Nasir A, Khan AU, Lodhi MA, Gul H, Khan F, Asad M, Parveen Z. Benzophenone Sulfonamide Derivatives as Interacting Partners and Inhibitors of Human P-glycoprotein. Anticancer Agents Med Chem 2020;20:1739-51. [PMID: 32416700 DOI: 10.2174/1871520620666200516144403] [Reference Citation Analysis]
24 Teng YN, Wang CCN, Liao WC, Lan YH, Hung CC. Caffeic Acid Attenuates Multi-Drug Resistance in Cancer Cells by Inhibiting Efflux Function of Human P-glycoprotein. Molecules 2020;25:E247. [PMID: 31936160 DOI: 10.3390/molecules25020247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
25 Bakos É, Német O, Patik I, Kucsma N, Várady G, Szakács G, Özvegy‐laczka C. A novel fluorescence‐based functional assay for human OATP1A2 and OATP1C1 identifies interaction between third‐generation P‐gp inhibitors and OATP1A2. FEBS J 2020;287:2468-85. [DOI: 10.1111/febs.15156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
26 Tonbul H, Sahin A, Tavukcuoglu E, Esendagli G, Capan Y. Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer. Journal of Drug Delivery Science and Technology 2019;54:101380. [DOI: 10.1016/j.jddst.2019.101380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Dash RP, Babu RJ, Srinivas NR. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clin Pharmacokinet 2018;57:1385-98. [PMID: 29682695 DOI: 10.1007/s40262-018-0655-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
28 Alam A, Kowal J, Broude E, Roninson I, Locher KP. Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science 2019;363:753-6. [PMID: 30765569 DOI: 10.1126/science.aav7102] [Cited by in Crossref: 156] [Cited by in F6Publishing: 138] [Article Influence: 52.0] [Reference Citation Analysis]
29 Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. Porto Biomed J 2019;4:e15. [PMID: 31595257 DOI: 10.1016/j.pbj.0000000000000015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
30 Traxl A, Mairinger S, Filip T, Sauberer M, Stanek J, Poschner S, Jäger W, Zoufal V, Novarino G, Tournier N, Bauer M, Wanek T, Langer O. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib. Mol Pharm 2019;16:1282-93. [PMID: 30694684 DOI: 10.1021/acs.molpharmaceut.8b01217] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
31 Alam A, Küng R, Kowal J, McLeod RA, Tremp N, Broude EV, Roninson IB, Stahlberg H, Locher KP. Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci U S A 2018;115:E1973-82. [PMID: 29440498 DOI: 10.1073/pnas.1717044115] [Cited by in Crossref: 97] [Cited by in F6Publishing: 77] [Article Influence: 24.3] [Reference Citation Analysis]
32 Rigalli JP, Scholz PN, Tocchetti GN, Ruiz ML, Weiss J. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect. Eur J Nutr 2019;58:139-50. [PMID: 29101532 DOI: 10.1007/s00394-017-1578-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
33 Giacone DV, Carvalho VFM, Costa SKP, Lopes LB. Evidence That P-glycoprotein Inhibitor (Elacridar)-Loaded Nanocarriers Improve Epidermal Targeting of an Anticancer Drug via Absorptive Cutaneous Transporters Inhibition. J Pharm Sci 2018;107:698-705. [PMID: 28935591 DOI: 10.1016/j.xphs.2017.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Syed SB, Arya H, Fu IH, Yeh TK, Periyasamy L, Hsieh HP, Coumar MS. Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep 2017;7:7972. [PMID: 28801675 DOI: 10.1038/s41598-017-08062-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 10.6] [Reference Citation Analysis]